csirt@kutim:~/threat-intel/cve/CVE-2026-16454

Katalog CVE

CVSS 4.3 · Medium EPSS 0,36%

Kerentanan Improper Access Control pada eclipse hawkbit. Skor CVSS 3.1 4.3 (Medium) menurut eclipse.org.

Deskripsi (NVD)

In Eclipse hawkBit versions 1.0.3 and prior, a privilege escalation vulnerability (CWE-284 / CWE-862) has been identified in the Direct Device Integration (DDI) Controller. This vulnerability allows an authenticated device to escalate its permissions and bypass the strict boundaries of its assigned updates. Under normal operation, a device should be restricted strictly to the specific firmware artifacts explicitly assigned to it. However, this flaw enables any authenticated device to bypass this restriction and download any firmware artifact within the same tenant. This is not an authentication bypass; the requesting device must possess valid credentials for its respective tenant. Instead, the issue stems from a flaw in object-level authorization validation. A related, lower-severity helper issue exists in the listing software modules artifacts metadata endpoint. This endpoint does not enforce assignment checks, enabling an authenticated device to list and enumerate available firmware artifacts, which can facilitate targeted exfiltration using the main download authorization bypass.

Rincian

Terbit di NVD
21 Juli 2026
Terakhir diubah
11 Agustus 2026
Status NVD
Analyzed
CVSS 3.1
4.3 (Medium), sumber eclipse.org
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-284: Improper Access Control
CWE-862: Missing Authorization
EPSS (30 hari)
0,36% peluang dieksploitasi; lebih tinggi dari 27,5% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
eclipse hawkbit Semua versi sebelum 1.0.4

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.